title: Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines.
abstract: The involvement of proteoglycans (PGs) in EBV-host interactions and lymphomagenesis remains poorly investigated. In this study, expression of major proteoglycans (syndecan-1, glypican-1, perlecan, versican, brevican, aggrecan, NG2, serglycin, decorin, biglycan, lumican, CD44), heparan sulphate (HS) metabolic system (EXT1/2, NDST1/2, GLCE, HS2ST1, HS3ST1/2, HS6ST1/2, SULF1/2, HPSE) and extracellular matrix (ECM) components (collagen 1A1, fibronectin, elastin) in primary B cells and EBV carrying cell lines with different phenotypes, patterns of EBV-host cell interaction and viral latency stages (type I-III) was investigated. Primary B cells expressed a wide repertoire of PGs (dominated by serglycin and CD44) and ECM components. Lymphoblastoid EBV+ B cell lines (LCLs) showed specific PG expression with down-regulation of CD44 and ECM components and up-regulation of serglycin and perlecan/HSPG2. For Burkitt's lymphoma cells (BL), serglycin was down-regulated in BL type III cells and perlecan in type I BL cells. The biosynthetic machinery for HS was active in all cell lines, with some tendency to be down-regulated in BL cells. 5'-aza-dC and/or Trichostatin A resulted in transcriptional upregulation of the genes, suggesting that low expression of ECM components, proteoglycan core proteins and HS biosynthetic system is due to epigenetic suppression in type I cells. Taken together, our data show that proteoglycans are expressed in primary B lymphocytes whereas they are not or only partly expressed in EBV-carrying cell lines, depending on their latency type program.
authors.affiliation: Institute of Molecular Biology and Biophysics, Novosibirsk, Russia.|Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institute, Stockholm, Sweden.
authors.forename: Alexandra Y
authors.initials: AY
authors.lastname: Tsidulko
authors.affiliation: Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institute, Stockholm, Sweden.
authors.forename: Liudmila
authors.initials: L
authors.lastname: Matskova
authors.affiliation: Kemerovo Institute of Food Science and Technology, Kemerovo, Russia.
authors.forename: Lidiia A
authors.initials: LA
authors.lastname: Astakhova
authors.affiliation: Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institute, Stockholm, Sweden.
authors.forename: Ingemar
authors.initials: I
authors.lastname: Ernberg
authors.affiliation: Institute of Molecular Biology and Biophysics, Novosibirsk, Russia.|Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institute, Stockholm, Sweden.
authors.forename: Elvira V
authors.initials: EV
authors.lastname: Grigorieva
mesh_terms: D001402:B-Lymphocytes / Q000378:metabolism* / Q000821:virology*; D015153:Blotting, Western; D002051:Burkitt Lymphoma / Q000378:metabolism / Q000821:virology; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D020031:Epstein-Barr Virus Infections / Q000378:metabolism*; D005434:Flow Cytometry; D004854:Herpesvirus 4, Human / Q000502:physiology; D006801:Humans; D010641:Phenotype; D011509:Proteoglycans / Q000096:biosynthesis*; D060888:Real-Time Polymerase Chain Reaction; D017735:Virus Latency
chemical_list: D011509:Proteoglycans
keywords: B cells; Epstein-Barr virus; heparan sulfate biosynthesis; lymphoma development; proteoglycan